Features and associated factors of bacterial skin infections in hospitalized patients with pemphigus: a single-center retrospective study

Furong Li
Peking University First Hospital

Yejun Wu
Peking University People's Hospital

Wenjie Bian
Peking University People's Hospital

Lei Huang
Peking University First Hospital

Xuejun Zhu
Peking University First Hospital

Xixue Chen
Peking University First Hospital

Mingyue Wang ( wangmy@pku.edu.cn )
Peking University First Hospital  https://orcid.org/0000-0001-8317-3414

Research

Keywords: bacterial skin infections, pemphigus, antibiotics, Gram stain, Staphylococcus aureus

DOI: https://doi.org/10.21203/rs.3.rs-37433/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Infections were the primary cause of death (34.3%-55.5%) in patients with pemphigus. Skin was usually the origin of infections. The study aimed to explore features and associated factors of bacterial skin infections (BSIs) in inpatients with pemphigus.

Methods: One hundred and eighty-four inpatients with pemphigus hospitalizing from November 2014 to April 2019 were continuously recruited through Peking University First Hospital’s inpatient records. Then, we retrieved the clinical and laboratory data to explore the characteristics and associated factors of BSIs.

Results: Of patients enrolled, pemphigus vulgaris (PV, n=142) and pemphigus foliaceus (PF, n=9) were most common, followed by pemphigus erythematosus (PE, n=25) and pemphigus vegetans (Pveg, n=1). Eighty-seven of 177 (49.2%) inpatients developed BSIs, and they had a longer length of stay compared with inpatients without BSIs (median: 18.9 days vs. 14.1 days, p = 0.008). Staphylococcus aureus was the most common bacteria (71.3%, 62/87) and highly resistant to penicillin (91.9%, 57/62). Higher levels of anti-Dsg1 autoantibodies (>124.2U/mL) (p<0.001, odds ratio [OR]=3.564, 95% confidence interval [CI]: 1.784-7.123) and anti-Dsg3 autoantibodies (>169.5U/mL) (p = 0.03, OR=1.074, 95% CI: 1.084-3.969) were underlying risk factors of BSIs when analyzed by binary regression analysis. As for Gram’s stain of bacteria, females had a lower rate of Gram-positive infections (p = 0.03). Patients using oral antibiotics (p = 0.05) had a higher rate of Gram-negative infections. Inpatients who were hospitalized in other hospitals within two weeks before the current admission had a higher rate of Gram-negative and co-infections (p = 0.03).

Conclusions: Inpatients with pemphigus had a high incidence of BSIs. Some factors were associated with the susceptibility of BSIs and bacterial species.

Introduction

Pemphigus is an autoimmune bullous disease characterized by flaccid blisters and erosions of skin/mucous membranes [1]. Annual incidence varies from 0.76 to 16.1 cases per million [2, 3]. Subtypes of pemphigus were differentiated by clinical features, histopathology, and specific autoantibodies [2]. Pemphigus vulgaris (PV) (65%) and pemphigus foliaceus (PF) (23%) are the most frequent subtypes [4]. Though the use of glucocorticoids and immunosuppressive agents has significantly diminished the mortality, the prognosis of pemphigus is still worse than that of the general population [2]. Infections are the most frequent complications of patients with pemphigus and account for 34.3%-55.5% of all death [5-8]. Besides, inpatients with pemphigus have a higher rate of serious infections than inpatients without a diagnosis of autoimmune bullous disease (50.4% vs. 25.4%) [9]. In pemphigus with serious infections, hospital expenses increase, and length of stay (LOS) extends [9]. Skin is usually the origin of infections [10]. Fragile barrier, dysfunction of immunity, and usage of systemic corticosteroids and/or other immunosuppressing agents may be the causes [5-8]. Therefore, the study aims to explore the features and associated factors for bacterial skin infections (BSIs), which may be helpful for the control of BSIs.
Materials And Methods

Patients and data collection

This was a retrospective study conducted at Peking University First Hospital starting in May 2019. The study followed the Declaration of Helsinki and was approved by the ethics committee of the hospital. One hundred and seventy-seven inpatients with pemphigus were continuously recruited from November 2014 to April 2019. Diagnostic criteria of pemphigus included: (1) flaccid blisters and erosions on skin or mucosa, (2) suprabasal/subcorneal loss of epidermal adhesion in histopathology, (3) IgG and/or C3 deposits on the surface of keratinocytes, and (4) seropositivity of anti-Dsg1 and/or anti-Dsg3 autoantibodies (MBL, Nagoya, Japan) [11]. Bacterial skin infections (BSIs) were diagnosed by purulent skin secretions, fever, elevated inflammatory markers (white blood cells, neutrophils, C-reactive protein, etc.), and culture of skin swabs. A culture of skin swab was necessary for the diagnosis of BSIs. If the isolated bacteria might be contaminating bacterium, clinical features and other laboratory examinations would be thoroughly considered for the diagnosis of BSIs. BSIs identified within the first 48 hours was identified as community-acquired infections [12]. The final diagnosis of BSIs was made by a consultant doctor in infectious diseases and a senior dermatologist. Body mass index (BMI) more than 28 kg/m\(^2\) was defined as obesity [13]. Hypoalbuminemia was defined as < 30 g/L [14].

Demographic characteristics, history of previous hospitalization, the severity of skin lesions, etc. were retrieved from the hospital inpatient databases. We mainly pulled levels of anti-desmoglein antibodies and albumin, white blood cell count, CRP, culture results, and antibiotic susceptibility test results out of the laboratory database. The treatment protocols within 2 weeks before this hospitalization were also collected. The severity of skin lesions graded as follows: mild, <10.0% body surface area (BSA); moderate, 10.0%-30.0% BSA; severe, 30.0%-50.0% BSA; extensive, ≥50.0% BSA. The systemic glucocorticoids was graded as follows (equivalent to prednisone): low dosage: < 0.5 mg/(kg\(\times\)d); medium dosage: ≥ 0.5 mg/(kg\(\times\)d) and <1.0 mg/(kg\(\times\)d); high dosage ≥ 1.0 mg/(kg\(\times\)d).

Bacterial identification and antimicrobial susceptibility testing

The specimens were streaked into both Columbia blood agar plates and China Blue agar plates at 35°C for 24-48 hours until single colonies were obviously seen. Then the single colony was sub-cultured when necessary. The pure colonies from the primary culture or sub-culture were selected for further bacterial identification.

Bacterial identification was performed by Bruker Daltonik MALDI Biotyper system (BD, USA), with MALDI Biotyper 3.1 software. For the bacteria with identification scores lower than 1.699, PCR amplification and DNA sequencing of 16S rRNA genes were performed as described previously [15].

Antimicrobial susceptibility testing was performed by VITEK-2 Compact automated system (BioMerieux, France) following the manufacturer's instructions, with AST-P639 card for \textit{S. aureus} isolates included in our study. The determined minimal inhibitory concentrations (MICs) were interpreted as susceptible,
intermediate, or resistant according to the breakpoints from Clinical and Laboratory Standards Institutes M100-S29 document, *S. aureus* ATCC 25923 was used as quality control in each set of tests [16].

Statistical analysis

Data were analyzed with IBM SPSS 24.0 (IBM Corp, Armonk, NY). Continuous variables were converted into categorical variables by the Receiver Operating Characteristics curve, by which anti-Dsg1 and anti-Dsg3 autoantibodies were grouped by 124.2 IU/ml and 169.5 IU/ml, respectively, and age was grouped by 53.5 years. Non-parametric tests were used for variables not meeting the normal distribution. Chi-square test or Fisher's exact test were used for group variables. Factors with *P* ≤ 0.10 were reanalyzed by binary regression analysis. *P* < 0.05 was considered statistically significant. See Figure 1 for the study and analysis flow chart.

Results

Clinical features

A total number of 177 inpatients were enrolled, including PV (80.2%, 142/177), pemphigus erythematosus (PE) (14.1%, 25/177), PF (5.1%, 9/177), and pemphigus vegetans (Pveg) (0.6%, 1/177). The median age was 50.4 years (range: 14-80 years), and the female/male ratio was 0.90. The incidence of diabetes mellitus (DM) (18.6%, 33/177), hypertension (27.7%, 49 /177), and osteoporosis (11.3%, 20/184) were high. Twelve (6.8%), 31 (17.5%), 52 (29.4%) and 82 (46.3%) of 177 patients had mild, moderate, severe and extensive skin lesions, respectively. Most inpatients (70.6%, 125/177) received oral glucocorticoids, and 114 (91.2%) of 125 had detailed records of the dosage. Of them, 43.9% (50/114) patients took medium dose (0.5mg/kg·d - 1.0mg/kg·d), and 24.6% (28/114) patients took high dose (≥ 1.0mg/kg·d) of prednisone or the equivalent. Eighty-seven of 177 (49.2%) inpatients developed BSIs. LOS was analyzed by a non-parametric test, and inpatients with BSIs had longer LOS compared with inpatients without BSIs (median: 18.9 days vs. 14.1 days, *p* = 0.008).

Bacterial spectrum and drug resistance

Eighty-seven of 177 (49.2%) patients developed BSIs, and 17 of 87 (19.5%) inpatients had multiple bacterial infections. If a patient, who was diagnosed with BSIs, had the isolations of both pathogenic bacteria and underlying contaminating bacteria, such as *Staphylococcus epidermidis* (*S. epidermidis*) or *streptococcus viridans*, it was hard to differentiate whether the *S. Epidermidis or streptococcus viridans* was contaminating bacteria or not. Therefore, we showed all the isolated bacteria of these inpatients. The Bacterial spectrum of all inpatients with BSIs was presented in Figure 2. Sixty-two (71.3%, 62/87) inpatients were infected with *Staphylococcus aureus* (*S. aureus*), followed by *Escherichia coli* (8.0%, 7/87), and *Methicillin-resistant coagulase-negative staphylococcus* (8.0%, 7/87). Eighty-one (93.1%, 81/87) inpatients presented with community-acquired infections. Patients with hospital-acquired infections had a higher incidence of *S. aureus* (83.3%, 5/6). The bacterial spectrum of community-acquired infections and hospital-acquired infection infections was illustrated in Figure 3.
It was a pity that many patients did not record the location of collected strains. Forty-three patients (43/87, 49.4%) detailed recorded the location of collected strains, including the scalp (13/43, 30.2%), the back (12/43, 27.9%), the axilla (12/43, 27.9%), and the other sites (33/43, 76.7%). The most common bacteria of the scalp, the back, and the axilla were *S. aureus* (7/13, 53.8%), *S. aureus* (8/12, 66.7%), and *Enterobacter cloacae* (3/12, 25.0%), respectively.

As for the drug resistance of *S. aureus*, penicillin G (91.9%, 57/62), erythromycin (75.8%, 47/62), and clindamycin (45.2%, 28/62) had the highest resistance rate. The resistance rate of rifampicin (1.6%, 1/62), linezolid (1.6%, 1/62), quinupristin (1.6%, 1/62), and tigecycline (1.6%, 1/62) was the lowest. All patients were sensitive to vancomycin (Figure 4). As the second most common bacteria, *Methicillin-resistant coagulase-negative staphylococcus* was also highly resistant to penicillin (100.0%, 7/7) and erythromycin (100.0%, 7/7). *Methicillin-resistant coagulase-negative staphylococcus* remained 100% sensitive to tigecycline and vancomycin.

### Risk factors for BSIs

Sex (p = 0.49), age (p = 0.96), obesity (p = 0.24), and smoke (p = 0.13) did not significantly associate with BSIs. Cerebrovascular disease (CVD) (p = 0.96), chronic heart disease (CHD) (p = 0.34), diabetes mellitus (DM) (p = 0.28), hypertension (p = 0.72), and osteoporosis (p = 0.58) did not associate with higher incidence of BSIs. Similarly, severity of skin lesions (p = 0.08), subtype of pemphigus (p = 0.51), and hypoalbuminemia (p = 0.09) were not underlying risk factors for BSIs. Higher levels of anti-Dsg1 autoantibodies (> 124.2U/mL) (p < 0.001) and anti-Dsg3 autoantibodies (>169.5U/mL) (p = 0.01) were associated with BSIs (Table 1). The variables with p ≤ 0.10 were reanalyzed by binary regression analysis and the results showed in Table 2. Higher levels of anti-Dsg1 autoantibodies (>124.2U/mL) (p < 0.001, odds ratio [OR]=3.564, 95% CI: 1.784-7.123) and anti-Dsg3 autoantibodies (>169.5U/mL) (p = 0.03, OR=2.074, 95% CI: 1.084-3.969) were significantly associated with BSIs.

### Associated factors for the type of bacteria

In inpatients with BSIs, 60 (69.0%, 60/87), 13 (14.9%, 13/87), and 14 (16.1%, 14/87) had infections of Gram-positive bacteria, Gram-negative bacteria and coinfections, respectively. Females had a higher rate of coinfection (54.3% vs. 35.7%) and a lower rate of Gram-negative infection (25.4% vs. 84.6%) compared to males (p = 0.03). Though the result was not significantly different, a higher rate of coinfections was observed in patients ≥53.5 years compared to ≥53.5 years’ (71.4% vs. 28.6%) (p = 0.37). Comorbidities, including CVD (p = 0.72), CHD (p = 0.72), DM (p = 0.39), hypertension (p = 0.86), and osteoporosis (p = 0.92), were not associated with Gram's stain. Bedridden was not significantly associated with Gram's stain (p = 0.09). Within 2 weeks before this admission, patients taking oral antibiotics had a higher rate of Gram-negative isolation (p = 0.05). Patients who were hospitalized in other hospitals within two weeks before the current admission had higher rates of Gram-negative infection and co-infections (p = 0.03) (Table 3).
Discussion/conclusion

Infection was the most common comorbidity in patients with pemphigus [9, 17], and increased hospital expenses and LOS [9]. Our study also found the LOS prolonged in inpatients with BSIs (p = 0.008). Ninety-four (49.2%, 87/177) inpatients with pemphigus developed BSIs in our research, parallel with another study (52%, 73/141) [18]. *S. aureus* was the most common type of bacteria [10, 19-21]. The drug resistance of *S. aureus* was striking [19]. *S. aureus* was highly resistant to penicillin (91.9%), erythromycin (75.8%), and clindamycin (45.2%). *S. aureus* was sensitive to vancomycin and moxifloxacin, which might be good choices for inpatients who need empirical and vigorous treatment.

Associated factors for BSIs were explored. Hsu et al. suggested that patients who had multi-morbidities and poor health conditions were more likely to develop lethal infections [17], and DM was associated with infections in many studies [1, 18, 19, 22]. However, comorbidities, such as DM, CVD, CHD, etc., were not significantly associated with BSIs in our study. Hypoalbuminemia was suggested to be associated with poor health conditions and had a higher rate of BSIs in previous studies [23, 24], but no association was observed in our analysis.

Many studies linked infections to immunosuppressive agents [25, 26]. Hsu et al. proposed that infection in patients with pemphigus was iatrogenic. The role of glucocorticoids and other immunosuppressive agents of infection was uncertain [17]. Glucocorticoids and immunosuppressive agents were not significantly associated with BSIs in our studies. It might be due to the influences of both immunosuppression and promoting recovery of skin lesions of these drugs. Although 82 of 177 (46.3%) patients had extensive skin lesions, only 43 of 177 (24.3%) patients accepted immunosuppressors before his hospitalization. The nonstandard treatment also influenced the association between immunosuppressors and BSIs.

Higher levels of anti-Dsg1 autoantibodies (>124.2U/mL) (p < 0.001) and anti-Dsg3 autoantibodies (>169.5U/mL) (p = 0.03) were significantly associated with BSIs. Patients with high levels of anti-Dsg1 autoantibodies or higher anti-Dsg3 autoantibodies had high disease activity and severe or even recalcitrant skin lesions [27-29], which could explain the phenomena. However, the association between the area of skin lesions and BSIs was not significant (p = 0.08) in our study, which might be because we only briefly calculated the area of skin lesions and did not consider the types of skin damage for the incomplete record.

We also paid attention to the associated factors of the type of bacteria. Female had higher incidence of coinfection (64.3% vs. 35.7%), and lower incidence of Gram-negative infection (15.4% vs. 84.6%) (p = 0.03) compared to males in our study. Different gender-related lifestyle and physical function might cause this difference [30-32]. The discrepancy of body-size, immune capacity, and energy availability between males and females might be the underlying reasons. Besides, Thompson et al. found that pathogen transmission and virulence were much higher in females [33]. Anyway, the underlying interesting mechanism of different infections in different gender was unclear and needed further studies. The use of systemic antibiotics was associated with a higher rate of Gram-negative infections.
Dysbacteriosis induced by antibiotics might be the reason [34]. Patients who were hospitalized in other hospitals within two weeks before the current admission (p = 0.03) had a higher rate of Gram-negative infection and co-infections. It was known that the bacteria spectrum of the hospital was different from the community. For example, the most common bacteria of community-acquired pneumonia was *Streptococcus pneumonia*, while the most common bacteria of hospital-acquired pneumonia was *Acinetobacter baumannii* and *Pseudomonas aeruginosa* [35, 36]. Iatrogenic manipulation and the use of antibiotics caused the difference of bacterial spectrum [37, 38]. So we should pay more attention to the infections of Gram-negative bacteria in inpatients with a history of previous hospitalization.

**Limitations**

The study has some limitations. This was a retrospective study in a single center, so the generalizability might be influenced, and selection bias existed. This study did not enroll outpatients with pemphigus, which might influence the spectrum of bacteria and drug resistance. The relatively small sample size was also a disadvantage of this study. Patients admitted to the tertiary hospital might be more serious, so the incidence of BSIs might be overestimated. Finally, the authors did not exclude the underlying contaminating bacteria in showing the species of isolated bacteria. Though the limitations exist, the results proposed in the study are beneficial to understand the BSIs and may be the basis for high-quality researches in the future.

**Conclusions**

The study found that inpatients with pemphigus had a high incidence rate of BSIs, and *S. aureus* was the most common isolated bacteria. High levels of anti-Dsg1 (>124.2U/mL) and Dsg3 autoantibodies (>169.5U/mL) might be underlying risk factors for BSIs. Besides, gender, systemic usage of antibiotics, and history of the previous hospitalization might influence the type of isolated bacteria. We highlighted the importance of further exploration of underlying risk factors of BSIs in inpatients with pemphigus.

**Abbreviations**

AIBD: autoimmune bullous disease; BMI: body mass index; BSA: body surface area; BSIs: bacterial skin infections; CHD: chronic heart disease; CI: confidence interval; CVD: cerebrovascular disease; DM: diabetes mellitus; LOS: length of stay; OR: odds ratio; PE: pemphigus erythematosus; PF: pemphigus foliaceus; PV: pemphigus vulgaris; Pveg: pemphigus vegetans.

**Declarations**

The study was approved by the ethics committee of Peking University First Hospital. All the authors were active participants: FL and YW were responsible for data collection and management, statistical analysis and interpretation, literature research, and manuscript writing; WB, XZ, and XC were responsible for data collection, statistical analysis, and interpretation; LH was responsible for data interpretation, diagnosis review, and method writing, especially for bacterial identification and antimicrobial susceptibility testing.
part; MW was responsible for the design of the study, statistical analysis and interpretation, and the revision of the paper. All authors read and approved the final manuscript.

The datasets of the current study are available from the corresponding author on reasonable request.

The authors declare that they have no competing interests.

The study was supported by the National Natural Science Foundation of China (grant number: 81000694 and 81130030) and the Beijing Natural Science Foundation (grant number: 7172214). The funders mainly cover the article publication charge but play no role in study design, data collection, data analysis, manuscript writing, or publication.

We wish to submit the manuscript for publication in Annals of Clinical Microbiology and Antimicrobials®, and the manuscript is not currently under consideration for publication in another journal.

**Acknowledgement**

This study was supported by the National Natural Science Foundation of China (grant number: 81000694 and 81130030) and the Beijing Natural Science Foundation (grant number: 7172214).

**References**

1. Leshem YA, Gdalevich M, Ziv M, David M, Hodak E, Mimouni D. Opportunistic infections in patients with pemphigus. J Am Acad Dermatol. 2014;71(2):284-92.
2. Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunol Res. 2018;66(2):255-70.
3. Porro AM, Hans Filho G, Santi CG. Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of Dermatology. An Bras Dermatol. 2019;94(2 Suppl 1):20-32.
4. Committee for Guidelines for the Management of Pemphigus D, Amagai M, Tanikawa A, Shimizu T, Hashimoto T, Ikeda S, et al. Japanese guidelines for the management of pemphigus. J Dermatol. 2014;41(6):471-86.
5. Lehman JS, Murrell DF, Camilleri MJ, Kalaaji AN. Infection and infection prevention in patients treated with immunosuppressive medications for autoimmune bullous disorders. Dermatol Clin. 2011;29(4):591-8.
6. Stanley JR. Pemphigus and Pemphigoid as Paradigms of Organ-Specific, Autoantibody-Mediated Diseases. J Clin Invest. 1989;83(5):1443-8.
7. Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zillikens D, Payne AS, et al. Pemphigus. Nat Rev Dis Primers. 2017;3:17026.
8. Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJP, West J. Bullous pemphigoid and pemphigus vulgaris - incidence and mortality in the UK: population based cohort study. Bmj-Brit Med
9. Ren Z, Narla S, Hsu DY, Silverberg JI. Association of serious infections with pemphigus and pemphigoid: analysis of the Nationwide Inpatient Sample. J Eur Acad Dermatol Venereol. 2018;32(10):1768-76.

10. Ahmed AR, Moy R. Death in pemphigus. J Am Acad Dermatol. 1982;7(2):221-8.

11. Kayani M, Aslam AM. Bullous pemphigoid and pemphigus vulgaris. BMJ. 2017;357:j2169.

12. Bajaj JS, O’Leary JG, Tandon P, Wong F, Garcia-Tsao G, Kamath PS, et al. Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis. Am J Gastroenterol. 2019;114(7):1091-100.

13. Cheng TO. Lower body mass index cut-off values for obesity in China. Nutr Rev. 2003;61(12):432.

14. Conner BJ. Treating Hypoalbuminemia. Vet Clin North Am Small Anim Pract. 2017;47(2):451-9.

15. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al. Diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635-8.

16. CLSI. Performance standards for antimicrobial susceptibility testing: twenty ninth informational supplement. CLSI Document M100-S29. 2019.

17. Hsu DY, Brieva J, Sinha AA, Langan SM, Silverberg JI. Comorbidities and inpatient mortality for pemphigus in the U.S.A. Br J Dermatol. 2016;174(6):1290-8.

18. Belgnaoui FZ, Senouci K, Chraibi H, Aoussar A, Mansouri F, Benzekri L, et al. [Predisposition to infection in patients with pemphigus. Retrospective study of 141 cases]. Presse Med. 2007;36(11 Pt 1):1563-9.

19. Esmaili N, Mortazavi H, Noormohammadpour P, Boreiri M, Soori T, Vasheghani Farahani I, et al. Pemphigus vulgaris and infections: a retrospective study on 155 patients. Autoimmune Dis. 2013;2013:834295.

20. Kiran KC, Madhukara J, Abraham A, Muralidharan S. Cutaneous Bacteriological Profile in Patients with Pemphigus. Indian J Dermatol. 2018;63(4):301-4.

21. Fagheei Aghmiyuni Z, Khorshidi A, Moniri R, Soori T, Musavi SG. The Prevalence of S. aureus Skin and Soft Tissue Infections in Patients with Pemphigus. Autoimmune Dis. 2016;2016:7529078.

22. Lehman JS, Khunger M, Lohse CM. Infection in autoimmune bullous diseases: a retrospective comparative study. J Dermatol. 2013;40(8):613-9.

23. Chang CP, Hsiao CT, Fann WC. Risk factors associated with bacteremia correlated with mortality in patients with acute bacterial skin and skin structure infection. Intern Emerg Med. 2019;14(2):259-64.

24. Kuo Chou TN, Chao WN, Yang C, Wong RH, Ueng KC, Chen SC. Predictors of mortality in skin and soft-tissue infections caused by Vibrio vulnificus. World J Surg. 2010;34(7):1669-75.

25. Galloway JB, Mercer LK, Moseley A, Dixon WG, Ustianowski AP, Helbert M, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2013;72(2):229-34.
26. Garcia-Doval I, Cohen AD, Cazzaniga S, Feldhamer I, Addis A, Carretero G, et al. Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registries. Journal of the American Academy of Dermatology. 2017;76(2):299-+.

27. Amagai M. Desmoglein as a target in autoimmunity and infection. Journal of the American Academy of Dermatology. 2003;48(2):244-52.

28. Payne AS, Hanakawa Y, Amagai M, Stanley JR. Desmosomes and disease: pemphigus and bullous impetigo. Curr Opin Cell Biol. 2004;16(5):536-43.

29. Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. New Engl J Med. 2006;355(17):1800-10.

30. Fang C, Chen XJ, Zhou MM. Epidemiology and Cytokine Levels among Children with Nosocomial Multidrug-Resistant Acinetobacter baumannii Complex in a Tertiary Hospital of Eastern China. Plos One. 2016;11:8.

31. Tsai MH, Lee IT, Chu SM, Lien R, Huang HR, Chiang MC, et al. Clinical and Molecular Characteristics of Neonatal Extended-Spectrum beta-Lactamase-Producing Gram-Negative Bacteremia: A 12-Year Case-Control-Control Study of a Referral Center in Taiwan. Plos One. 2016;11:8.

32. Vasudevan A, Memon BI, Mukhopadhyay A, Li JL, Tambyah PA. The costs of nosocomial resistant gram negative intensive care unit infections among patients with the systemic inflammatory response syndrome- a propensity matched case control study. Antimicrob Resist In. 2015;4(1):3.

33. Thompson O, Gipson SAY, Hall MD. The impact of host sex on the outcome of co-infection. Sci Rep. 2017;7(1):910.

34. Medina E, Pieper DH. Tackling Threats and Future Problems of Multidrug-Resistant Bacteria. Curr Top Microbiol Immunol. 2016;398:3-33.

35. Mandell LA. Community-acquired pneumonia: An overview. Postgrad Med. 2015;127(6):607-15.

36. Chung DR, Song JH, Kim SH, Thamlikitkul V, Huang SG, Wang H, et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med. 2011;184(12):1409-17.

37. Cohen B, Spirito CM, Liu JF, Cato KD, Larson E. Concurrent Detection of Bacterial Pathogens in Hospital Roommates. Nurs Res. 2019;68(1):80-3.

38. Hamel M, Zoutman D, O'Callaghan C. Exposure to hospital roommates as a risk factor for healthcare-associated infection. Am J Infect Control. 2010;38(3):173-81.

Tables

Table 1. Associated factors of BSIs by univariate analysis.
| Features                     | Without BSIs (n=90) | BSIs (n=87) | P-value |
|------------------------------|---------------------|-------------|---------|
| **Sex**                      |                     |             | 0.49    |
| Female (n=84)                | 45 (50.0)           | 39 (44.8)   |         |
| Male (n=93)                  | 45 (50.0)           | 48 (55.2)   |         |
| **Age**                      |                     |             | 0.96    |
| <53.5 years (n=100)          | 51 (56.7)           | 49 (56.3)   |         |
| ≥53.5 years (n=77)           | 39 (43.3)           | 38 (43.7)   |         |
| **Obesity (n=25)**           | 10 (11.4)           | 15 (17.6)   | 0.24    |
| **Smoke (n=16)**             | 11 (12.2)           | 5 (5.7)     | 0.13    |
| **Alcohol intake (n=11)**    | 8 (8.9)             | 3 (3.4)     | 0.13    |
| **Comorbidities**            |                     |             |         |
| CVD (n=7)                    | 3 (3.3)             | 4 (4.6)     | 0.96    |
| CHD (n=5)                    | 1 (1.1)             | 4 (4.6)     | 0.34    |
| Diabetes mellitus (n=33)     | 14 (15.6)           | 19 (21.8)   | 0.28    |
| Hypertension (n=49)          | 26 (28.9)           | 23 (26.4)   | 0.72    |
| Osteoporosis (n=20)          | 9 (10.0)            | 11 (12.6)   | 0.58    |
| Bedridden (n=2)              | 0 (0.0)             | 2 (2.3)     | 0.24    |
| Previous hospitalization (n=18) | 10 (11.1)       | 8 (9.2)     | 0.67    |
| **The severity of skin lesions** |                  |             | 0.08    |
| Mild (n=12)                  | 9 (10.0)            | 3 (3.4)     |         |
| Moderate (n=31)              | 20 (22.2)           | 11 (12.6)   |         |
| Severe (n=52)                | 24 (26.7)           | 28 (32.2)   |         |
| Extensive (n=82)             | 37 (41.1)           | 45 (51.7)   |         |
| **Subtype of pemphigus**     |                     |             | 0.51    |
| PV and P Veg (n=143)         | 71 (78.9)           | 72 (82.8)   |         |
| PE and PF (n=34)             | 19 (21.1)           | 15 (17.2)   |         |
| **Therapy**                  |                     |             |         |
| Antibiotics (n=40)           | 20 (22.2)           | 20 (23.0)   | 0.90    |
| Glucocorticoids (n=129)      | 65 (72.2)           | 64 (73.6)   | 0.84    |
| Immunosuppressive agent (n=43)| 26 (28.9)         | 17 (19.5)   | 0.15    |
| Hypoalbuminemia (n=21)       | 7 (8.0)             | 14 (16.3)   | 0.09    |
| Anti-dsg1 autoantibodies 2   |                     |             | <0.001  |
| ≤124.2 IU/ml (n=61)          | 44 (50.6)           | 17 (20.5)   |         |
| >124.2 IU/ml (n=109)         | 43 (49.4)           | 66 (79.5)   |         |
| Anti-dsg3 autoantibodies 3   |                     |             | 0.01    |
| ≤169.5 IU/ml (n=93)          | 56 (64.4)           | 37 (44.6)   |         |
| >169.5 IU/ml (n=77)          | 31 (35.6)           | 46 (55.4)   |         |
1 Four patients (without BSIs=2, BSIs=2) had no records of BMI so that these patients could not be assessed for obesity.

2 Seven patients had no records of levels of anti-dsg1 autoantibodies (without BSIs=3, BSIs=4).

3 Seven patients had no records of levels of anti-dsg3 autoantibodies (without BSIs=3, BSIs=4).

Abbreviations: CVD, cerebrovascular disease; CHD, coronary heart disease; PV, Pemphigus vulgaris; PVeg, pemphigus vegetans; PE, pemphigus erythematous; PF, pemphigus foliaceus; Dsg, desmoglein; BSIs, bacterial skin infections; BMI, body mass index.

Table 2. Associated factors of BSIs by binary regression analysis.

| Variables                  | OR (95% CI)     | P-value |
|----------------------------|-----------------|---------|
| i-Dsg1 autoantibodies      |                 | <0.001  |
| 124.2 IU/mL                | 1.00            |         |
| 124.2 IU/mL                | 3.564 (1.784-7.123) |         |
| i-Dsg3 autoantibodies      |                 | 0.03    |
| 169.5                      | 1.00            |         |
| 169.5                      | 2.074 (1.084-3.969) |         |

Abbreviations: BSIs, bacterial skin infections; Dsg, desmoglein; OR, odds ratio; CI, confidence interval;

Table 3. Associated factors of Gram stain of bacteria in patients with pemphigus by univariate analysis.
| Features                          | Gram-positive (n=60, %) | Gram-negative (n=13, %) | Coinfection (n=14, %) | P-value |
|----------------------------------|------------------------|-------------------------|-----------------------|---------|
| **Sex**                          |                        |                         |                       | 0.03    |
| Female (n=39)                    | 28 (46.7) a, b         | 2 (15.4) b              | 9 (64.3) a            |         |
| Male (n=48)                      | 35 (54.7) a, b         | 11 (84.6) b             | 5 (35.7) a            |         |
| **Age**                          |                        |                         |                       | 0.37    |
| <53.5 years (n=49)               | 31 (51.7)              | 8 (61.5)                | 10 (71.4)             |         |
| ≥53.5 years (n=38)               | 29 (48.3)              | 5 (38.5)                | 4 (28.6)              |         |
| **Obesity (n=15)**               | 8 (13.3)               | 5 (41.7)                | 2 (15.4)              | 0.10    |
| **Smoke (n=5)**                  | 5 (8.3)                | 0 (0.0)                 | 0 (0.0)               | 0.15    |
| **Alcohol intake (n=3)**         | 2 (3.3)                | 1 (7.7)                 | 0 (0.0)               | 0.47    |
| **Comorbidities**                |                        |                         |                       |         |
| CVD (n=4)                        | 2 (3.3)                | 1 (7.7)                 | 1 (7.1)               | 0.72    |
| CHD (n=4)                        | 2 (3.3)                | 1 (7.7)                 | 1 (7.1)               | 0.72    |
| Diabetes mellitus (n=19)         | 11 (18.3)              | 3 (23.1)                | 5 (35.7)              | 0.39    |
| Hypertension (n=23)              | 16 (26.7)              | 4 (30.8)                | 3 (21.4)              | 0.86    |
| Osteoporosis (n=11)              | 7 (11.7)               | 2 (15.4)                | 2 (14.3)              | 0.92    |
| Bedridden (n=2)                  | 0 (0.0)                | 1 (7.7)                 | 1 (7.1)               | 0.09    |
| Previous hospitalization (n=8)   | 2 (3.3) a              | 3 (23.1) b              | 3 (21.4) b            | 0.03    |
| **The severity of skin lesions** |                        |                         |                       | 0.40    |
| Mild (n=3)                       | 1 (1.7)                | 1 (7.7)                 | 1 (7.1)               |         |
| Moderate (n=11)                  | 7 (11.7)               | 3 (23.1)                | 1 (7.1)               |         |
| Severe (n=28)                    | 17 (28.3)              | 4 (30.8)                | 7 (50.0)              |         |
| Extensive (n=45)                 | 35 (58.3)              | 5 (38.5)                | 5 (35.7)              |         |
| **Subtype of pemphigus**         |                        |                         |                       | 0.92    |
| PV and P Veg (n=72)              | 49 (81.7)              | 11 (84.6)               | 12 (85.7)             |         |
| PE and PF (n=15)                 | 11 (18.3)              | 2 (15.4)                | 2 (14.3)              |         |
| **Therapy**                      |                        |                         |                       |         |
| Topical antibiotics (n=10)       | 5 (8.3)                | 3 (23.1)                | 2 (14.3)              | 0.35    |
| Systemic antibiotics (n=11)      | 4 (6.7) a              | 4 (30.8) b              | 3 (21.4) a, b         | 0.05    |
| Topical glucocorticoids (n=7)    | 6 (10.0)               | 1 (7.7)                 | 0 (0.0)               | 0.27    |
| Systemic glucocorticoids (n=62)  | 40 (66.7)              | 10 (76.9)               | 12 (85.7)             | 0.29    |
| Immunosuppressive agents (n=17)  | 13 (21.7)              | 2 (15.4)                | 2 (14.3)              | 0.75    |
| Hypoalbuminemia (n=14)           | 8 (13.6)               | 3 (23.1)                | 3 (21.4)              | 0.61    |
Anti-Dsg1 autoantibodies

| Level         | ≤124.2 IU/mL (n=17) | >124.2 IU/mL (n=66) |
|---------------|---------------------|---------------------|
|               | 9 (16.1)            | 47 (83.9)           |
|               | 3 (23.1)            | 10 (76.9)           |
|               | 5 (35.7)            | 9 (64.3)            |

Anti-Dsg3 autoantibodies

| Level         | ≤169.5 IU/mL (n=37) | >169.5 IU/mL (n=46) |
|---------------|---------------------|---------------------|
|               | 26 (46.4)           | 30 (53.6)           |
|               | 6 (46.2)            | 7 (53.8)            |
|               | 5 (35.7)            | 9 (64.3)            |

1 Two patients (Gram-positive=0, Gram-negative=1, Coinfection=1) had no records of body mass index so that these patients could not be assessed for obesity.

2 Four patients had no records of levels of anti-dsg1 autoantibodies (Gram-positive=4, Gram-negative=0, Coinfection=0).

3 Four patients had no records of levels of anti-dsg3 autoantibodies (Gram-positive=4, Gram-negative=0, Coinfection=0).

Abbreviations: CVD, cerebrovascular disease; CHD, coronary heart disease; PV, Pemphigus vulgaris; PVeg, pemphigus vegetans; PE, pemphigus erythematosus; PF, pemphigus foliaceus; Dsg, desmoglein.

Figures
Figure 1
Flow diagram of the study.
**Figure 2**

Bacteria spectrum of inpatients with pemphigus.
Figure 3

Bacteria spectrum of community-acquired infections and hospital-acquired infections.
Figure 4

Drug resistance of Staphylococcus aureus.